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FEMALE SEXUAL DYSFUNCTION: THE IMPORTANT
POINTS TO REMEMBER
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Antonio Marmo Lucon
PASQUALOTTO EB et al. Female sexual dysfunction: the important points to remember. CLINICS 60(1):51-60, 2005.
Media exposure regarding male sexual dysfunction and the growing number of viable treatment alternatives for
erectile dysfunction has resulted in increasing numbers of men seeking clinical appointments and treatment for the condition,
which has previously been considered taboo. Because these problems usually arise within the context of relationships, some
investigators have alluded to increased rates of sexual dysfunction among the partners of these men. Also, since general
practitioners, gynaecologists, geriatrists, and urologists are also seeing female patients for evaluation of various types of
dysfunction, certain groups of these women with underlying chronic conditions have been noted to have high rates of
concomitant sexual dysfunction. Physicians who have good rapport with these patients are in a privileged position to help
with these intimate problems, which are often difficult for patients to discuss. Therefore, it is of extreme importance that
these professionals become knowledgeable about and comfortable with the initial evaluation and possible treatment of
female sexual dysfunction.
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There is an ongoing change in the field of female sexual
function and dysfunction.1,5 The number of general practi-
tioners, researchers, and institutions treating female sexual
dysfunction (FSD) appears to be growing every year.6-8 Gen-
eral practitioners, gynecologists, geriatrists, and urologists
are attending groups of women with underlying chronic
conditions with increased rates of concomitant sexual dys-
function.5,9,10 Physicians who have a good rapport with these
patients are in a unique position to help with these inti-
mate problems, which are often difficult for patients to dis-
cuss. Therefore, it is of utmost importance to general prac-
titioners, gynecologists, geriatrists, and urologists to be-
come knowledgeable about and comfortable with the ini-
tial evaluation and possible treatment of FSD.
Prevalence of Female Sexual Dysfunction
Sexual dysfunction can be defined as “the persistent
impairment of a couple’s normal or usual patterns of sexual
interest and/or response”. Pioneering works by Kinsey in
1953 and, subsequently, Masters and Johnson in 1966 pro-
vided insights into the range of normative sexual function
and the physiologic processes underlying sexual stimula-
tion.11 Since these studies, the media have popularized the
results of these and other studies, challenging many myths
and turning the human sexual function into a daily topic
of conversation, while at the same time possibly indicating
false standards of normalcy through the misrepresentation
of data. For instance, misinterpretation of Masters and
Johnson’s research on multiple orgasms in the female may
result in feelings of inadequacy and dysfunction in a
woman who does not experience multiple orgasms.12 Well-
designed, randomly-sampled, community-based epidemio-
logic investigations of women with sexual dysfunction are
limited. Current data reveal that up to 76% of women have
some type of sexual dysfunction. The U.S. population cen-
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sus data suggest that nearly 10 million American women
aged 50 to 74 self-report complaints of diminished vaginal
lubrication, pain and discomfort on intercourse, decreased
arousal, and difficulty in achieving orgasm.13,14 Recently,
Laumann and Rosen found that sexual dysfunction is more
prevalent in women (43%) than in men (31%) and is asso-
ciated with various psychodemographic characteristics such
as age, education, and poor physical and emotional health.15
More importantly, FSD is associated with negative sexual
relationship experiences. Despite the high prevalence of
sexual dysfunction in women, there are very few centers
worldwide that practice comprehensive and multi-
disciplinary investigation and management of sexual dys-
function in women.
There are few data regarding the incidence and preva-
lence of FSD. Presently available epidemiologic studies of
sexual dysfunction suffer from a variety of methodological
problems, including small sample size, skewed sample
populations, failure to sample nonresponders, and lack of
a uniform definition of sexual dysfunction. These short-
comings notwithstanding, Hawton states that women report
more sexual problems than men, with a prevalence rate of
35% to 60%; disorders of desire and arousal are the most
common complaints.16
Age and relationship status are significant predictors of
sexual satisfaction, with older women reporting a higher
prevalence of sexual difficulty.17-19 Also, despite their sexual
difficulties, more than half of women reported being from
somewhat to very satisfied with their overall sexual rela-
tionship. Therefore, relationship satisfaction for women may
not be determined entirely by sexual function. Moreover,
many women may tolerate a certain level of sexual dysfunc-
tion before considering it a source of relationship dissatis-
faction.
Evaluation of Female Sexual Dysfunction
In some cases, it may be necessary for physicians to care-
fully inquire into sexual functioning, paying special atten-
tion to the sensitivity of the topic and to the patient’s com-
fort levels. Validated sexual questionnaires, such as the Fe-
male Sexual Function Index20 and the Sexual Distress Scale21
may be helpful tools in the evaluation of sexual function.
The cornerstone of the patient evaluation is a comprehen-
sive and detailed sexual, medical, and psychosocial history;
physical examination; and focused laboratory testing22-25 are
essential. Specialized diagnostic tests such as biothesio-
metry or genital vascular studies (duplex Doppler ultra-
sound), although not always indicated, may corroborate the
impressions gained at the initial evaluation. It should be
stressed that the secondary psychological reaction to these
organic factors must not be ignored.24,25
Despite the prevalence of FSD, many women may be
too embarrassed or reluctant to initiate a discussion of their
sexual problems.1-4 Unassuming questions such as, for in-
stance “Are you sexually active?” followed by “Do you
have any questions or concerns regarding your sexual
health?” may be all that is needed to establish confidence
in a rapport leading to further inquiry. The more
longstanding the sexual dysfunction, the more difficult it
becomes to treat. Since general practitioners, gynecologists,
geriatrists, and urologists will be seeing an increasing
number of women with either overt or covert sexual dys-
function, it has become prudent to learn how best to treat
or refer appropriately.
Assessment of FSD begins with a thorough case history,
physical examination, and appropriate laboratory studies
(Table 1). In addition, it must be determined whether these
problems are new or chronic in duration, arise from specific
or more general situations, or are byproducts of a relational
or deep-rooted emotional conflict.
History
Delineate any prior history of childhood sexual abuse,
incest, rape, or sexual harassment, and arrange for appro-
priate counseling (Table 1).26-29 Sexual expectations of both
partners should be assessed for compatibility. Also, seek
overt or covert current relationship or social or job stress
that may be causing anxiety.
Table 1 - Evaluation of female sexual dysfunction.
Physical examination History Laboratory studies
Senile atrophy vagina Sexual abuse Complete blood count
Vault erythema, discharge Parity status Thyroid-stimulating hormone
Prolapse Menstrual status Human immunodeficiency virus
Strictures, scars Depression, anxiety Urinalysis
Cervical motion tenderness Comorbidities Toxins
Bimanual examination Abdominal, pelvic surgery PAP smear
Levator ani myalgia Medications
Vulvar vestibulitis Substance abuse
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There are several landmark physiological events in a
woman’s life that may affect her current sexual function.25,29
Sexual interest and activity often decline as pregnancy
progresses, although there are few medical restrictions con-
cerning coitus during pregnancy, except for the third trimes-
ter. Women who breast-feed may be more likely to report de-
creased sexual desire or increased coital pain. This may be
secondary to the elevated prolactin levels that occur during
lactation and inhibit ovarian function, resulting in lower tes-
tosterone (desire) and estrogen (vaginal discomfort) levels.
There appears to be a biologically driven periovulatory peak
of female sexual desire associated with increases in serum
levels of testosterone and androstenedione.30
Although somewhat controversial, a number of reports
associate menopause with decreased female sexual function,
suggesting a possible hormonal mechanism for female sexual
function; however, the exact hormonal milieu of normal fe-
male sexual function continues to be incompletely under-
stood.13,16,18,27 Although estrogen replacement therapy may
restore vaginal epithelial function, increase vaginal flow, and
improve the overall sense of well-being in postmenopausal
woman, it is not a guarantee of sexual well-being.31,32 Some
researchers have documented a decrease in sexual desire be-
lieved to be secondary to testosterone deficiency in those
premenopausal women who have undergone oophorectomy;
however, postmenopausal women demonstrate more variabil-
ity in hormone-sensitive sexual desire than testosterone-de-
ficient men.32,33 In addition to hormonal changes, there are
many psychosocial factors concomitant with the onset of the
menopause, including questions of aging and body image
that may have an impact on sexual function.
A variety of medical conditions have been associated
with a disposition to FSD.1-3,34-37 Spinal cord injury may af-
fect sexual function and, although controversial, women
with spinal cord lesions at T1 and below are probably
anorgasmic.1,29,36 In addition, women who have neurologic
diseases such as Parkinson’s disease or multiple sclerosis
may have sexual problems.1,34 Chronic diseases affecting
multiple systems such as thyroid dysfunction or diabetes
may have an impact upon the female sexual function.38 Pa-
tients who have had traumatic head injury may experience
decreased sexual desire, and many temporal lobe epilep-
tics have been shown to have a decreased sexual drive.24
Unfortunately, depression is a major risk factor for sexual
dysfunction, and any chronic disease may result in depres-
sion, making delineation of etiology of sexual dysfunction
somewhat problematic.
It is important to know whether the patient has any his-
tory of abdominal/pelvic trauma, sexually transmitted dis-
ease, or pelvic inflammatory disease. Prior surgical proce-
dures including abdominal–perineal resection, pelvic ex-
enteration, retroperitoneal lymphadenectomy, sympathec-
tomy, or aortoiliac surgery may have either a mechanical
or neurological effect on sexual function.4,6 Hysterectomy
may foreshorten the vaginal vault or result in internal scar-
ring that prevents full ballooning of the vagina.39,40 In ad-
dition, loss of the uterus results in diminished total
vasocongestion and loss of uterine contractions with stimu-
lation, which some women find bothersome. Whether su-
pracervical hysterectomy preserves more complete sexual
functioning, remains a matter of debate. Further, any his-
tory of prior pelvic radiation therapy may cause FSD.
Current knowledge regarding the sexual side effects of
certain medications is not as well defined for women as it
is for men.41,42 It is mainly the adverse sexual side effects of
various psychotropic medications that have been charac-
terized in women.42,43 Caution in evaluating these data is
in order, because research indicates that many patients who
have underlying psychiatric disorders may have had a low
prior level of sexual function, and the sedative or extrapy-
ramidal side effects of these medications may further limit
the sexual function.44
Major tranquilizers such as diazepam are believed to
limit sexual function secondary to a dopaminergic action.
Antipsychotic medications such as thioridazine and flu-
phenazine have been reported to cause orgasmic dysfunc-
tion.25,41-43 Antidepressant medications such as imipramine
cause deleterious sexual side effects in up to 75% of pa-
tients treated. Selective serotonin reuptake inhibitors
(SSRIs) seem to cause decreased sexual desire and inhib-
ited orgasm more frequently than monoamine oxidase in-
hibitors or tricyclic antidepressants. Interestingly, treatment
with fluoxetine has been reported to result in the produc-
tion of the spontaneous sensation of orgasm.42,43 Alcohol
and drugs of abuse can alter the sexual response. Occupa-
tional or environmental exposure to toxins such as lead,
mercury, pesticides, and any vinyl chloride, among others,
may also affect sexual function.25
Physical Examination
In addition to a comprehensive physical examination,
attention should be drawn to the female pelvic
exam.4,6,8,28,29,37 Examine the introitus for signs of senile mu-
cosal atrophy or discharge; the presence erythema, or of any
signs suggestive of vaginitis should be noted.24,29,38 Find-
ings based on bimanual examination may suggest endome-
triosis, varices of the broad ligament, ovarian adhesions or
tenderness, adnexal masses, or pelvic inflammatory diseases.
Rectal tone, masses, and any tenderness or fluid in the pos-
terior cul-de-sac should be evaluated. The posterolateral rec-
tal support should be assessed for levator ani myalgia.40,45
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Laboratory Studies
Laboratory evaluation must be tailored to the findings
of the history and physical examination.24,38 A complete
blood count may reveal anemia or suggest occult malig-
nancy that may underly malaise, depression, and decreased
libido. A fasting biochemical profile should prove useful
in the evaluation of renal, adrenal, hepatic, pancreatic, thy-
roid, or parathyroid function. Urinalysis may reveal infec-
tion or occult diabetes. Optional but sometimes useful labo-
ratory tests include thyroid-stimulating hormone, the hepa-
titis panel, testosterone, progesterone, LH, FSH, prolactin,
hemoglobin A1C, erythrocyte sedimentation rate, human
immunodeficiency virus, and serum toxin levels (such as
lead or mercury). Performance of Pap smears or cervical and
vaginal cultures should be based on the findings of the
physical examination. Clinical suspicion should guide the
use of imaging modalities such as ultrasonography and
Computed Axial Tomography scan (CT).
Diagnostic modalities such as duplex Doppler ultra-
sound, vaginal and clitoral temperature, vibration sensory
testing, and selective pudendal arteriogram expand physi-
cian’s and patient’s understanding of the pathophysiologic
mechanisms of the SD; however disadvantages such as in-
vasiveness, cost, the associated risks/complications, and the
lack of normative data have limited the use of these spe-
cialized tests.11,24,38,46,47 Noninvasive vascular testing of
women with sexual dysfunction has been reported by
several investigators. These include vaginal photo-
plethysmography and genital duplex Doppler ultrasound.
Vaginal photoplethysmography, the most widely used vas-
cular testing technique, measures vaginal mucosal engorge-
ment and vaginal blood volumes, providing quantitative
data on the extent of vaginal vasocongestion. The major
drawbacks of this diagnostic tool are that it produces arbi-
trary rather than absolute units of measurement. In addition,
it is susceptible to subject movement artifact and baseline
drift.
The role of duplex Doppler ultrasonography in the man-
agement of women with sexual dysfunction remains to be
determined. However, several investigators have reported
small patient series using duplex Doppler ultrasound be-
fore and after stimulation (visual and vibratory) as a diag-
nostic tool in females with sexual dysfunction.11,24,38,46,47
Clitoral shaft diameter is measured from the medial tu-
nica albuginea of the corporal body across the septum to
the lateral tunica albuginea of the contralateral corporal
body.38,47 The angle of the clitoral shaft formed by the sus-
pensory ligament is the sonographic landmark used for
volumetric measurements. Maintaining this sonographic
landmark, the small parts probe is then swept laterally to
evaluate the hypoechoic, ill-defined, carrot-shaped corpus
spongiosum that possesses a thin, occasionally visualized
tunica, and the corpus spongiosum diameter is measured.47,48
Hemodynamic data (peak systolic, end diastolic, and resis-
tive index values) from the corpus spongiosum and
cavernosal arteries are measured. One of the limitations of
the current ultrasonographic methodology is the lack of the
standardized use of topical vasoactive agents to maximize
genital smooth muscle relaxation.
What is normal sexual function?
Originally, Masters and Johnson outlined a progressive
3-phase sexual response cycle, consisting of arousal, or-
gasm, and resolution.12 Subsequently, sexologists attempt-
ing to treat patients who chronically fail to initiate or re-
spond to sexual stimuli added an initial phase of desire to
the sexual response cycle.12,24,38 The American Psychiatric
Associations’ Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) classifies the sexual response cycle in
4 related but neurophysiologically discrete phases: appe-
tite, desire, or libido; arousal or excitement; orgasm or cli-
max; and refractory or resolution.12 Currently, researchers
are considering whether a fifth phase, namely satisfaction,
would help to further distinguish certain patients with
sexual dysfunction.
Desire
Sexual desire appears to be controlled by a dopamine-
sensitive excitatory center balanced against a serotonin-sen-
sitive inhibitory center.38 In both males and females, testo-
sterone is responsible for programming these centers in pre-
natal life and for maintaining their threshold of response.49-
51
 Desire is modulated by connections between these centers
and other parts of the brain.11,50 The net effect of these posi-
tive and negative influences modulates genital sexual re-
sponse via impulses passing down the spinal cord to the
reflex centers that govern excitement and orgasm.
Excitement
During the excitement phase, vascular engorgement oc-
curs, mediated primarily by the parasympathetic nervous
system.11,24,38 Genital changes include enlargement in the
diameter and length of the clitoris, dilation of perivaginal
arterioles with seeping of vascular transudate across the
vaginal epithelium resulting in lubrication, and expansion
of the upper half of the vagina.46,47 Estrogen is the hormone
responsible for maintaining the vaginal mucosa and allow-
ing transudation and lubrication to occur. Afferent stimuli
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travel via the dorsal nerve of the clitoris to the pudendal
nerve to sacral centers. Efferent stimuli occur via the pel-
vic nerve to the uterovaginal plexus.11,24,38,46,47
Orgasm
During the orgasmic phase, a series of reflex clonic con-
tractions of the elevator sling and related genital muscula-
ture occur, mediated primarily via the sympathetic nervous
system.24,25 Extragenital reactions during orgasm include
contraction of muscle groups throughout the body and el-
evations of heart rate, blood pressure, and respiratory rate.38
Excitement and orgasm are reflexes.38 For the orgasmic
reflex to be activated, the stimulus must be applied where
the sensory nerve endings are located (primarily in the area
of the clitoris), and stimulation must be of sufficient inten-
sity and duration to reach the threshold for the reflex.
What is sexual dysfunction?
Sexual dysfunction in women is defined as any disor-
der related to sexual desire, arousal, orgasm, and/or sexual
pain that results in significant personal distress and may
have an impact on the quality of life.11 Although each spe-
cific condition can be defined separately in medical terms,
there is a clinically significant overlap in afflicted patients.
True sexual dysfunction is manifested by failure of one or
more phases of the sexual response cycle: desire, excite-
ment, and orgasm (Table 2).11,12 However, according to
DMS-IV, sexual dysfunctions should be categorized with
reference to the earliest phase of the sexual response cycle
during which disruptions occur.24,38 Therefore, the manage-
ment of patients with FSD begins with the identification
and diagnosis of the problematic relationships and is based
on the patient’s self-report in conjunction with a clinical
evaluation.24 the disturbance frequently begins with orgas-
mic disturbance, but if neglected, loss of excitement and
finally loss of desire may follow. Sexual dysfunction may
be further subdivided into three categories: primary (real-
istic sexual expectations have never been met under any
circumstances); secondary (all phases have functioned in
the past, but one or more no longer do so); or situational
(the response cycle functions in some circumstances, but
not in others).37
The following is a brief discussion of the categories by
which one may identify sexual dysfunction.
Hypoactive Sexual Desire Disorder
Some 30% to 50% of patients in sex therapy clinics
present with complaints of hypoactive sexual desire disor-
der, defined as the persistent or recurrent absence or deficit
of sexual activity.37,38,51 There are two major concerns in this
diagnosis: 1) there are no norms for sexual desire stratified
by age; and 2) the reasons for the development and main-
tenance of this complaint vary. This suggests that its
etiology is heterogeneous.
Important physical factors that affect sexual desire in-
clude general health status, depression, hormonal status, and
use of both prescribed and recreational drugs.41-44 Tricyclic
antidepressants, monoamine oxidase inhibitors, lithium,
and certain antipsychotics are among the medications re-
ported to decrease sexual interest.42-44
Psychological and interpersonal factors are often in-
volved.9,37 Such factors, which can diminish sexual desire,
include sudden events such as job loss, or the loss of a fam-
ily member; cumulative events such as a woman’s response
to aging and menopause; life milestones such as a child’s
leaving home; and ongoing relationship stress.
Appropriate treatment depends on the underlying
etiology. Generalized and lifelong low sexual desire sug-
gests the need for screening for endocrine disorders, chronic
illness, or long-term medication use.8,11,24,26,38 The use of tes-
tosterone has been shown to increase desire, but its long-
term use may be limited by potential side effects including
cardiovascular and liver dysfunction. Antidepressants may
help depression-related low desire, although many of these
medications at least initially decrease sexual desire.41-43
If there is no causative medical disorder, individual or
couples therapy is often to be recommended. However,
hypoactive sexual desire is one of the more difficult disor-
ders to treat, with one study suggesting success rates of less
than 50%.24 The more long-standing the disorder, the more
resistant it is to treatment.
Sexual Aversion Disorder
Persistent or recurrent aversion to and avoidance of geni-
tal contact with a sexual partner; known as sexual aversion
disorder, is a much less common disorder.38 Low sexual de-
sire and occasionally vaginismus or dyspareunia usually
Table 2 - Categories of female sexual dysfunctions.
Sexual desire disorders
Hypoactive sexual desire
Sexual aversion
Sexual arousal disorder
Orgasmic disorder
Sexual pain disorders
Dyspareunia
Vaginismus
Sexual satisfaction
Sexual dysfunctions not otherwise specified
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accompany it.24,38 Women with this disorder may have a his-
tory of sexual or physical abuse. They may have extensive
negative, unexpressed feelings about their relationships.9
Specific aversions that are phobic in nature, such as aver-
sion to semen, may be difficult to overcome.
Sexual Arousal Disorder
Partial or total lack of physical signs of arousal during
sexual stimulation in women without concomitant meno-
pausal, dyspareunia, or anorgasmic symptoms is rare.24,36
Physical and subjective sexual arousal are not necessarily
correlated in women. However, a continued lack of lubri-
cation may lead to discomfort during sex, thus impairing a
woman’s subjective arousal, and could possibly be inter-
preted by her sexual partner as a lack of interest, which may
eventually result in a distressed sexual relationship.
A thorough review of possible physical causes for this
complaint constitutes the initial evaluation.11,37,38 Recom-
mendations on the use of topical lubricants or estrogenic
compounds should be based on the woman’s physical con-
dition, age, and risk factors for estrogen therapy.52,53
Orgasmic Disorders
Persistent delay in achieving orgasm or its absence is a
common sexual complaint.24,25,37,38 Approximately 10% of
women report a lifelong lack of orgasm, and at least 50% of
women report situational or intermittent orgasmic problems.
Physical causes of orgasmic dysfunction may include pel-
vic or spinal surgery or trauma or the use of certain medica-
tions (such as various antidepressants and antipsychotics).24,36
Seldom does a physical cause underlie primary lifelong or-
gasmic disorder. Psychological and interpersonal factors, such
as the woman’s family values regarding sex or unpleasant
earlier sexual experiences, may contribute to lack of orgasm.9
Male partners of anorgasmic women frequently feel respon-
sible for the woman’s lack of orgasm, which can further com-
pound the relationship tension.
Effective treatments for orgasmic disorders include mas-
turbation and traditional sex therapy techniques. Success
rates in the 90% range for becoming orgasmic during mas-
turbation and in the 75% range for attaining orgasm with a
partner have been reported following therapy.24,25,27,37,38
Dyspareunia
Recurrent genital pain before, during, or after sexual in-
tercourse is known as dyspareunia.11,38 A careful physical
examination to precisely identify the anatomic sites and the
abnormalities causing pain is necessary prior to treat-
ment.24,25 Anatomic factors associated with dyspareunia such
as scar tissue, pelvic inflammatory disease, vaginal steno-
sis, or endometriosis often improve with medical or surgi-
cal treatment.25
Pain of a diffuse, long-term nature is more difficult to
treat.24,25 In such instances, referral for psychotherapy may
prove beneficial. Treatment strategies may include reliance
on noncoital sexual expression, counseling focused on less
painful coital positions, the use of antidepressants to treat
chronic pain syndromes, and anxiety reduction through
behavior modification.24,25,28
Vaginismus
Recurrent, involuntary spasm of the outer third of the
vagina interfering with intercourse is known as vaginis-
mus.11,25,26 In many patients experiencing vaginismus,
stresses such as relationship distress or the desire for preg-
nancy are prominent causative factors.9,11,26 Psychological
factors typically include strong sexual inhibition, sexual
trauma, unexpressed negative feelings toward a sexual part-
ner, or a pain-tension cycle that maintains itself independ-
ently of overt psychological factors.9
The cornerstone of treatment is centered on the use a
series of graduated dilators coupled with relaxation tech-
niques.9 Gradual involvement of the partner includes his in-
troduction of the dilators, then fingers, and finally gradual
insertion of the penis under the woman’s guidance and con-
trol. For severely phobic women, additional techniques and
systematic desensitization may be necessary.9,24,25,37,38
Indications for Referral
Physicians with appropriate training in sexual medicine
should manage the vast majority of women with sexual dys-
function.11,24,37,38 However, there are several indications for
referrals:
1. Young patients with history of pelvic/perineal trauma;
2. Patients with anorgasmia due to traumatic pudendal neu-
ropathy or hysterectomy;
3. Patients with genital pain due to neuromas, vestibular
adenitis myofascial pain syndrome, etc;
4. Patients with aortic aneurysm or bulbosacral disc dis-
ease that requires vascular or neurosurgical intervention;
5. Patients with complicated endocrinopathies;
6. Patients with complicated psychiatric or psychosexual
disorders (e.g. refractory depression, transsexualism);
7. Patient´s or physician´s request for specialized evalua-
tion;
8. Forensic reasons (occupational or iatrogenic injuries).
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Specialized Diagnostic Testing
Neurogenic causes of FSD are currently being investi-
gated. There have been anecdotal reports of the potential
lubrication-enhancing effects of phentolamine and
sildenafil.54,56 Recently, a study published by Kaplan et al.,
showed that only 6 of the 33 patients treated with sildenafil
had a significant therapeutic response (> 60% improvement
in the index of female sexual function).13 This study sug-
gests that sildenafil is safe but has limited efficacy in treat-
ing postmenopausal women with self-described sexual dys-
function. Overall sexual function did not improve signifi-
cantly, although there were changes in vaginal lubrication
and clitoral sensitivity. The role of various agents in treat-
ing this heretofore under-addressed problem will be an ex-
citing avenue of research in the future.
Treatment of Sexual Dysfunction in Women
Modifying Reversible Causes
Health professionals should work with patients to
modify reversible causes of FSD such as psychogenic FSD,
hormonal imbalances, hyperprolactinemia, specific drug-
related FSD (e.g. selective serotonin reuptake inhibitors -
SSRIs), vascular or neurologic sexual dysfunction second-
ary to blunt perineal trauma, and anorgasmia due to puden-
dal neuropathy.8,11,24,25,37,38
Sex steroid hormones
The role of sex steroid hormones in reproductive func-
tion has been extensively investigated and has contributed
significantly to the successful clinical management of women
with infertility by sex hormones or hormone analogues.52,53
However, the role of sex steroid hormones in regulating vagi-
nal arousal has been poorly investigated. At present, there is
no rationale for pharmacological management of women with
sexual dysfunction by sex hormones or hormone analogues.
Sarrel reported that women with plasma estradiol levels less
than 50 pg/mL had significantly more complaints of vagi-
nal dryness, frequency, and intensity of dyspareunia and
burning compared to women with estradiol values greater
than 50 pg/mL.57 Several investigators have shown that treat-
ment with estradiol increases vaginal blood flow and lubri-
cation, improves epithelial maturation indices, normalizes
vaginal pH, and prevents vaginal atrophy.24,38 Androgen re-
placement in women with sexual dysfunction is associated
with changes in the external genitalia including increased
sensitivity, engorgement, and hypertrophy of the clitoris and
vulvar hyperemia.24,45 Exogenous administration of androgens
has resulted in a significant increase in subjective ratings of
sexual arousal in postmenopausal women. Treatment of
women with adrenal insufficiency with dehydroepian-
drosterone (DHEA) improved overall well-being and sexual
function.58,59
Hyperprolactinemia
The treatment of hyperprolactinemia in women with
sexual dysfunction consists of 1) cessation of the medica-
tion causing hyperprolactinemia (e.g., estrogens, methyl-
dopa), 2) administration of bromocryptine, or 3) the surgi-
cal ablation or extirpation of a pituitary prolactin-secret-
ing tumor.11,24,35
Iatrogenic/drug-induced
Psychotropic agents such as SSRIs, neuroleptics, and
antipsychotics have been associated with sexual dysfunc-
tion in women.41-43 In addition, LH-RH agonists and
antiandrogens, commonly used in the treatment of endome-
triosis, infertility, and uterine fibromas are also associated
with sexual dysfunction.24,25
Psychogenic
Patients with any kind of destructive behavior, alcohol-
ism, cigarette smoking, or recreational drug use should be
counseled on the potential etiologic role of these factors
in FSD.9
Genital pain
Genital pain is a highly prevalent (14%), incapacitat-
ing, devastating condition associated with significant per-
sonal distress and diminished quality of life. Genital neu-
romas and vestibular adenitis may be successfully treated
by excision of the affected area.24,25
FIRST LINE THERAPY
Oral erectogenic agents (eg sildenafil, apomorphine, oral
phentolamine), vacuum erection devices, and psychosexual
or couple therapy should be regarded as first-line interven-
tions, on account of ease of administration, reversibility,
noninvasive nature, and low cost..
Oral Vasoactive Agents
Sildenafil, a potent and selective PDE 5 inhibitor that
blocks the hydrolysis of cGMP, enhances the accumulation
of cGMP and increases the relaxing effects of NO on the clito-
ris, but it is not currently FDA-approved for use in
women.14,22,34,43,44,55,60 Sildenafil has been utilized in the treat-
ment of women with sexual arousal disorders with mixed re-
sults.43,44,55,60 Clinical studies evaluating the efficacy and
safety of this drug in women are currently being undertaken.
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Phentolamine
Phentolamine is a nonselective adrenergic antagonist
that decreases adrenergic tone, thus facilitating
vasocongestion and delaying detumescence.56 A pilot (sin-
gle dose of oral phentolamine (40 mg) and placebo in a
single-blind, dose-escalation) study of 6 postmenopausal
women with a lack of lubrication and sexual arousal diffi-
culties reported a mild, positive effect across all measures
of arousal, with significant changes in self-reported lubri-
cation and pleasurable sensations in the vagina.56 Interest-
ingly, it has been shown that the physiological readings and
the subjective reports were significantly different from pla-
cebo in the women using estrogen replacement therapy with
40 mg of phentolamine in a vaginal solution. Further stud-
ies are needed to assess the potential value of phentolamine
and other vasoactive agents in the treatment of FSD.
Vacuum devices
At the time of writing, this type of therapy is the only
FDA-approved treatment for women with sexual dysfunc-
tion.24,25,38 It is designed to increase blood flow to the clito-
ris facilitating clitoral engorgement and enhancing periph-
eral genital sexual arousal. It is generally accepted that clito-
ral stimulation and engorgement are important aspects of
female sexual arousal. It is believed that the difficulty or
inability to achieve maximal clitoral tumescence may be
related to and associated with other symptoms of female
sexual arousal disorder. The postulated increase in blood
flow to the clitoris is associated with increased sensation
and enhanced sexual arousal including increased vaginal
lubrication and labial engorgement.
Sexual Therapy: Individual or Couple
Sexual therapy addressing relationship distress, sexual
performance concerns, and dysfunctional communication
patterns is likely to enhance sexual functioning.9,18,24 It is
recommended that both patient and partner should be in-
volved in the sexual therapy. Sexual therapy is also indi-
cated and beneficial in patients or couples who desire to
resume sexual activity after a prolonged period of absti-
nence. Lastly, sexual therapy is effective in addressing psy-
chological reactions to medical or surgical treatment.
Second and third line therapies
Unfortunately, there are no second, or third line thera-
peutic strategies available for the management of women
with sexual dysfunction.
CONCLUSION
In general, the longer-standing the sexual dysfunction,
the more difficult it becomes to treat. In addition, the ear-
lier the sexual response cycle is interrupted, the more resil-
ient to treatment it potentially becomes. Therefore, disor-
ders of the desire phase are generally harder to treat than
disorders of the arousal phase, which in turn are more diffi-
cult to treat than orgasmic dysfunction. Finally, multiple
interrelationship sexual dysfunctions such as female
anorgasmia coupled with male premature ejaculation, tend
to have a synergistic effect and are often more difficult to
treat than either alone. As we continue to learn more about
the specifics of the sexual response cycle, exciting new
treatments will emerge.
It is not the intention of this article to suggest that urolo-
gists, geriatrists, or primary care physicians should become
the primary caregivers for female sexual health rather than
gynecologists. However, it is wise for us to educate our-
selves in the identification of female patients with sexual
dysfunction. Moreover, as we become more aware of both
the basis of diagnosis and of therapy, we can counsel and
either effectively treat, or appropriately refer these patients.
RESUMO
PASQUALOTTO EB e col. Disfunção sexual feminina: o que
é importante saber. CLINICS 60(1):51-60, 2005.
A intensa exposição pela mídia do tema disfunção sexual
masculina e o número crescente de tratamentos disponíveis
para a disfunção erétil têm resultado num número crescente
de homens que procuram consulta e tratamento clínico para
este problema, antes considerado como “tabu”. Uma vez que
o problema geralmente surge no contexto do relacionamento,
alguns investigadores aludem às taxas crescentes de disfunção
sexual nas parceiras destes homens. Além disso, clínicos,
ginecologistas, geriatras e urologistas igualmente estão
avaliando pacientes do sexo feminino quanto a vários tipos
de disfunção. Em alguns grupos de mulheres com condições
crônicas subjacentes, também têm sido observado um
aumento nas taxas de disfunção sexual concomitante.
Médicos que tenham estabelecido uma boa relação médico-
paciente estão em posição única para ajudar com este
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problema, que em virtude de sua própria característica de
intimidade, geralmente é de difícil abordagem para os
pacientes. Desta forma, é de extrema importância que estes
profissionais tenham conhecimento e sintam-se à vontade
para iniciar a avaliação e possivelmente o tratamento da
disfunção sexual feminina.
UNITERMOS: Mulher. Feminina. Sexual. Disfunção.
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